Broker recommendations for Canopy Growth Corp.
The Canopy Growth Corp. stock is rated at 1.880952 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 8 October, 2020 by a total of 21 brokers. This means that the consensus of the 21 different brokers is leaning toward to moderate buy/hold.
2 (9.52%) Underweight
0 (0%) Hold
14 (66.67%) Overweight
1 (4.76%) Buy
Canopy Growth (TSX:CGC): Mexico Could Legalize Marijuana in 2020!
Saturday, 17 October 2020, 16:30:52
Investor sentiment about Canopy Growth (TSX:WEED)(NYSE:CGC) stock is about as bleak as it’s ever been. This could be the perfect time to buy before Mexico legalizes marijuana. The post Canopy Growth (TSX:CGC): Mexico Could Legalize Marijuana in 2020! appeared first on The Motley Fool Canada .
— The Motley Fool Canada
Is Canopy Growth Stock a Buy? | The Motley Fool
Saturday, 17 October 2020, 13:12:00
It’s a leader among cannabis companies, but a laggard when it comes to breaking even on the bottom line.
— The Motley Fool
How Berner’s Cookies Preserves Cannabis Quality Across State Lines
Friday, 16 October 2020, 16:55:48
As a cannabis entrepreneur, getting complimented by Bruce Linton can surely be something to brag about. If the executive chairman of Gage Cannabis — and former CEO of Canopy Growth Corp (NYSE: CGC ) — praises your business decisions, it’s likely a sign you’re on the right track. But if you’re a Billboard-charting rapper like Berner, you might be used to being praised. In a fireside chat at the Benzinga Cannabis Capital Conference on Thursday, Linton said that Berner opened his eyes to the fact that focusing on genetics and breeding drives market share, because consumers want new and better cannabis products. The Cookies, Gage Cannabis Partnership: For Linton, Berner’s brand Cookies stands out in the cannabis landscape for its ability to create a premium brand around flower. That might explain … Full story available on Benzinga.com
‘Psychedelics renaissance’: Startups turning magic mushrooms into medicine are racing to go public
Thursday, 15 October 2020, 16:37:00
Summary List Placement The psychedelics industry is booming. Compass Pathways , a London-based psychedelics giant, raised $146.6 million in its US initial public offering last month, and is valued at more than $1 billion. Psychedelics companies Field Trip Health and Havn Life Sciences recently started trading in Canada, following MindMed, which secured a Canadian listing in March. Meanwhile, the psychedelics industry is drawing attention from biotech investors , as well as from cannabis companies looking for fresh opportunities. The total market for psychedelics-related medicines could eventually reach $100 billion, according to a report from Tania Gonsalves at Cannacord Genuity. Companies are working on psychedelics-based therapies for treatment-resistant depression, cluster headaches, opioid use disorder, smoking cessation, and PTSD among others, according to the report. Ronan Levy, the founder and executive chairman of Field Trip , which is focused on setting up treatment clinics and on psychedelics-based drug development and manufacturing, called the uptick in investor interest and funding a “psychedelic renaissance.” A focus on the importance of mental health has gone mainstream, Levy said.
— Business Insider
Medical Cannabis Market (Covid 19 Update) Emerging Technology, Investor Analysis and Worldwide Forecast till 2027 || Canopy Growth Corporation, GW Pharmaceuticals plc., Aurora Cannabis., Aphria Medical Cannabis
Wednesday, 14 October 2020, 11:26:37
Data Bridge Market Research has recently added a concise research on the Medical cannabis market to depict valuable insights related to significant market trends driving the industry. Medical cannabis market report comprises of crucial aspects of the market that contains industry research, market
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.